Turning Point Therapeutics Inc
Turning Point Therapeutics — Investor Presentation (October 2021)
46 slides from Turning Point Therapeutics's investor presentation, Oct 8, 2021
Slide 1: Next-Generation Precision Oncology Medicines Company Overview
October 2021 Next-Generation Precision Oncology Medicines Company Overview Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development activities, plans and projected timelines, bus
Slide 3: Lead Candidate Repotrectinib; Robust Pipeline with Four Clinical Stage Drug Candidates
Lead Candidate: Repotrectinib with 2 Breakthrough Therapy Designations¹ NSCLC Other Solid Tumors Robust Pipeline with Four Clinical Stage Drug Candidates Developing potential best-in-class drug candidates Inhibitor of JAK2, SRC and FAK Combination potential with KRAS-targeting agents, with first coh
Slide 4: Ongoing Clinical Studies Against Well Validated Oncogenic Targets
Discovery Preclinical Early Stage Clinical Development Late Stage Clinical Development Repotrectinib (ROS1/TRK) TRIDENT-1: Advanced NSCLC (ROS1) and solid tumors (NTRK) CARE: Pediatric advanced solid tumors TRIDENT-2: KRAS-targeting combination Elzovantinib (TPX-0022) (MET) SHIELD-1: Advanced solid
Slide 5: Single Agent and Combination Opportunities To Treat Patients with Biomarker Driven Cancers
Single Agent 4,5 6 4,7-8 9-12 4,5 13-15 4,16 Combos 4,17-19 20-24 25-29 Single Agent and Combination Opportunities To Treat Patients with Biomarker Driven Cancers ¹ American Cancer Society 2020. ² Bailey MH, et al: Cell 2018. ³ Estimates rounded and include locally advanced and metastatic population
Slide 6: Repotrectinib: A Highly Selective ROS1/TRK Inhibitor
Repotrectinib: A Highly Selective ROS1/TRK Inhibitor
Slide 7: Repotrectinib: Potential Best-in-Class ROS1 and NTRK Targeted Therapy
ATP Kinase Repotrectinib Solvent-Front mutation Gatekeeper mutation Highly potent, structurally differentiated: small (low molecular weight), compact, with a rigid 3D macrocycle Designed to bind completely inside the ATP pocket even in the presence of solvent front or gatekeeper mutations Potential
Slide 8: TRIDENT-1: Ongoing Phase 1/2 Study of Repotrectinib
TRIDENT-1: An Ongoing Phase 1/2 Study of Repotrectinib in Patients with Advanced Solid Tumors Harboring ROS1, NTRK1-3 Rearrangements
Slide 9: TRIDENT-1 Study Design and Preliminary Phase 1+2 Data
TRIDENT-1 Study Design and Preliminary Phase 1+2 Data ROS1+ Advanced NSCLC NTRK+ Advanced Solid Tumors EXP-1 ROS1 TKI naïve (n=55) EXP-2 1 prior ROS1 TKI AND 1 platinum-based chemotherapy (n=60) EXP-3 2 prior ROS1 TKIs AND No prior chemotherapy (n=40) EXP-4 1 prior ROS1 TKI AND No prior chemotherapy
Slide 10: ROS1+ TKI-Naïve Advanced NSCLC: Preliminary Clinical Activity
ROS1+ TKI-Naïve Advanced NSCLC: Preliminary Clinical Activity Overall Response (N=22) N=22 patients with baseline and at least two post baseline scans N=15 Phase 2 patients N=7 Phase 1 patients treated at or above the Phase 2 recommended dose As of 31 December 2020, the 16th patient in Phase 2 has a
Slide 11: ROS1+ TKI Naïve Advanced NSCLC: Duration of Treatment
ROS1+ TKI Naïve Advanced NSCLC: Duration of Treatment Note: Presented at World Lung 2020 in Jan-2021. Data cutoff of 31-Dec-2020. † Includes patients with a baseline and at least two post-baseline scans; Phase 1 data includes only patients treated at or above repotrectinib RP2D. PD: progressive dise
Slide 12: ROS1+ TKI-Pretreated Advanced NSCLC: Preliminary Clinical Activity
ROS1+ TKI-Pretreated Advanced NSCLC: Preliminary Clinical Activity Overall Response (Phase 1 + Phase 2) N=72 EXP-2 EXP-3 EXP-4 Phase 2 (N=16) Phase 1 + 2 (N=23) Phase 2 (N=9) Phase 1 + 2 (N=10) Phase 2 (N=36) Phase 1 + 2 (N=39) Confirmed ORR (cORR) (95% CI) 31% (11 – 59) 39% (20 – 61) 33% (7 – 70) 3
Slide 13: ROS1+ TKI-Pretreated NSCLC with Baseline ROS1 Resistance Mutations
ROS1+ TKI-Pretreated Advanced NSCLC with Baseline ROS1 Resistance Mutations: Preliminary Clinical Activity Overall Response (Phase 1 + Phase 2) N=18 # Patient with solvent front mutation * Patient with gatekeeper mutation + Patient with other kinase domain mutation Maximum % Change from Baseline in
Slide 14: ROS1+ TKI-Pretreated Advanced NSCLC: Duration of Treatment
ROS1+ TKI-Pretreated Advanced NSCLC: Duration of Treatment Duration of Treatment (Phase 1 + Phase 2) N=72 EXP-2 EXP-3 EXP-4 Phase 1 + 2 (N=23) Phase 1 + 2 (N=10) Phase 1 + 2 (N=39) Duration of Treatment (range in months) 0.7 – 44.5+ 0.5 – 18.1+ 0.5 – 19.2+ Patients remaining on treatment – n (%) 5 (
Slide 15: NTRK+ TKI-Naive Advanced Solid Tumors: Preliminary Clinical Activity
NTRK+ TKI-Naive Advanced Solid Tumors: Preliminary Clinical Activity Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. Data cutoff date 26-Aug-2021 for Phase 2 and 22-Jul-2019 for Phase 1. Phase 2: RECIST v1.1 assessed by Physician Assessment with a data cutoff date of 26-Aug-2021. Phase 1:
Slide 16: NTRK+ TKI-Naive Advanced Solid Tumors: Duration of Treatment
NTRK+ TKI-Naive Advanced Solid Tumors: Duration of Treatment Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. Patient on treatment for 30.7+ months has not had BICR assessment of scans since 22-Jul-2019; per physician assessment, patient was in response for 7.4 months. Phase 2 data cutoff d
Slide 17: NTRK+ TKI-Pretreated Advanced Solid Tumors: Preliminary Clinical Activity
NTRK+ TKI-Pretreated Advanced Solid Tumors: Preliminary Clinical Activity Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. *At time of the 26-Aug-2021 data cut off, 3 patients in Phase 2 EXP-6 had unconfirmed PR (uPR). Two uPRs have been confirmed since the 26-Aug-2021 data cut off and are
Slide 18: NTRK+ TKI-Pretreated Tumors with NTRK Resistance Mutations
NTRK+ TKI-Pretreated Advanced Solid Tumors with NTRK Resistance Mutations: Preliminary Clinical Activity Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. **At time of the 26-Aug-2021 data cut off, 3 patients in Phase 2 EXP-6 with a resistance mutation had unconfirmed PR (uPR). Two uPRs have
Slide 19: NTRK+ TKI-Pretreated Advanced Solid Tumors: Duration of Treatment
NTRK+ TKI-Pretreated Advanced Solid Tumors: Duration of Treatment Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. Phase 2 data cutoff date 26-Aug-2021 (responses confirmed by Physician Assessment). Phase 1 data cutoff date 22-Jul-2019 for responses confirmed by BICR and 26-Aug-2021 for dur
Slide 20: Safety Summary: Phase 1 and Phase 2 Combined
Safety Summary: Phase 1 and Phase 2 Combined All Treated Patients (N=301) All Treated Patients (N=301) TEAEs (≥15% of patients) TRAEs Adverse Events All Grades n (%) Grade 3 n (%) Grade 4 n (%) Grade 3 n (%) Grade 4 n (%) Dizziness 181 (60.1) 7 (2.3) 0 7 (2.3) 0 Dysgeusia 132 (43.9) 1 (0.3) 0 1 (0.3
Slide 21: Repotrectinib Regulatory Update
Repotrectinib Regulatory Update For ROS1+ NSCLC, anticipated FDA meeting in 1H 2022 to discuss topline BICR results in at least 50 TKI-naïve and 50 TKI-pretreated patients with at least 6 months of follow-up For NTRK+ TKI-pretreated advanced solid tumors, Type B meeting with FDA anticipated in 1H 20
Slide 22: Repotrectinib Combinations in KRAS-Driven Tumors
Repotrectinib Combinations in KRAS-Driven Tumors
Slide 23: Repotrectinib Selectivity Profile Potentially Expands Opportunity Beyond ROS1 and TRK
Inhibits JAK2, SRC and FAK Leads to suppression of STAT3 and AKT signaling, major mechanisms of resistance Demonstrated synergy with trametinib (MEK inhibitor) in mutant KRAS NSCLC, CRC and pancreatic cancer cell lines Demonstrated synergy with AMG510, inhibiting KRASG12C tumor cell proliferation, s
Slide 24: Repotrectinib / Trametinib Combination in KRAS G12D Models
Repotrectinib / Trametinib Combination Exhibits Greater Tumor Growth Inhibition in KRAS G12D Syngeneic and PDX Lung Cancer Models mLU6045 KRAS G12D Note: Data presented at 2021 annual AACR meeting. 1500 1000 500 0 Tumor Volume mm3 (SEM) 0 5 10 15 20 25 Days of Treatment Vehicle BID Repotrectinib 15
Slide 25: Repotrectinib Enhances Survival with AMG510 in KRASG12C Xenograft Model
Repotrectinib combination shows a significant survival benefit in NSCLC KRASG12C xenograft model Builds on prior preclinical studies showing synergy with AMG510, inhibiting KRASG12C tumor cell proliferation, suppressing receptor tyrosine kinase upregulation, reducing KRASG12C tumor cell cytokine rel
Slide 26: TRIDENT-2: Phase 1b/2 Study of Repotrectinib Combinations
TRIDENT-2: Phase 1b/2 Study of Repotrectinib Combinations for the Treatment of KRAS Mutant Cancers, Currently in Dose Finding Key Subject Entry Criteria: KRAS mutant advanced cancer (KRAS mutation type(s) to be defined for each cohort) Measurable disease per RECIST v1.1 Asymptomatic CNS disease allo
Slide 27: SHIELD-1: Ongoing Phase 1 Study of Elzovantinib (TPX-0022)
SHIELD-1: An Ongoing Phase 1 Study of Elzovantinib (TPX-0022) in Patients with Advanced Solid Tumors Harboring Genetic Alterations in MET
Slide 28: Phase 1 SHIELD-1 Study of Elzovantinib in MET Alterations
Phase 1 SHIELD-1 Study of Elzovantinib (TPX-0022) in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET *Solid Tumors with MET Fusions or Oncogenic KD Mutations OR MET-amplified other than GI/NSCLC OR otherwise eligible for Cohorts I, III, or IV and >2 lines prior systemic ther
Slide 29: Elzovantinib was generally well tolerated
Elzovantinib was generally well tolerated Most common TEAE was dizziness, likely due to off target TRK inhibition Dose modifications due to TEAE 21 (38.9%) patients with TEAEs leading to dose reduction 3 (5.6%) patients with TEAEs leading to drug discontinuation 2 DLTs at 120 mg QD* All Grade periph
Slide 30: Preliminary Efficacy by Investigator Assessment
Preliminary Efficacy by Investigator Assessment Efficacy Outcomes TKI-Naïve Efficacy Evaluable Patients (N=32) Efficacy Outcomes NSCLC (N=11) GC/GEJ (N=9) Other Tumor Types (N=12) Best Overall Response PR – n (%) 4 (36) 3 (33) 1 (8) SD – n (%) 3 (27) 3 (33) 7 (58) PD – n (%) 4 (36) 3 (33) 4 (33) cOR
Slide 31: Preliminary Clinical Activity: TKI-Naïve NSCLC and GC/GEJ
Preliminary Clinical Activity by Investigator Assessment TKI-Naïve NSCLC and GC/GEJ Efficacy Evaluable Subjects (n=20) ↑ ∞ # Patient remains on treatment ↑ Patient has presence of both MET fusion and MET amplification ∞ uPR followed by PD Deepening response from 15Oct2020 data Preliminary Efficacy T
Slide 32: Duration of Treatment: TKI-Naïve NSCLC and GC/GEJ
Duration of Treatment TKI-Naïve NSCLC and GC/GEJ Efficacy Evaluable Subjects (n=20) Duration of Treatment NSCLC (n=11): 3.4 weeks to 78.6+ weeks GC/GEJ (n=9) : 4.4 weeks to 68.1+ weeks Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. Data cut-off date August 23, 2021 GC/GEJ, gastric cancer/
Slide 33: Elzovantinib Regulatory Update
Elzovantinib Regulatory Update Recent End of Phase 1 meeting with the FDA focused on next steps in patients with NSCLC In initial feedback, FDA recommended exploring an intermediate dose level using the QD titration to BID dosing strategy in at least 6 to 10 patients prior to starting the Phase 2 po
Slide 34: SWORD-1: Ongoing Phase 1 Study of TPX-0046 in RET Tumors
SWORD-1: An Ongoing Phase 1 Study of TPX-0046 in Patients with Advanced Solid Tumors Harboring RET Fusion or Mutation
Slide 35: TPX-0046 is a Potent Next Generation RET Tyrosine Kinase Inhibitor
Compact macrocycle with a small binding interface Potently inhibits wildtype RET and multiple RET mutations in cellular assays, demonstrates tumor regression in xenograft models VEGF sparing, potential to provide improved safety over approved agents Potential opportunity in TKI-naïve and TKI-pretrea
Slide 36: Phase 1/2 SWORD-1 Study Design of TPX-0046
Phase 1/2 SWORD-1 Study Design of TPX-0046 in Patients with Advanced Solid Tumors Harboring RET Fusion or Mutation, Currently in Dose Finding * Additional doses and/or schedules may be explored. Population Adults with advanced solid tumors RET fusion or mutation assessed by local testing No limit on
Slide 37: TPX-0046: Preliminary Safety Summary
TPX-0046 has been generally well tolerated Most AEs were Grade 1 or 2 Most common TEAE was dizziness Infrequent dose modifications due to TEAE 4 (19%) patients with TEAEs that led to dose reduction 2 (10%) patients with TEAEs that led to drug discontinuation MTD not reached; 1 DLT at 30 mg QD* No tr
Slide 38: TPX-0046: Preliminary Efficacy by Investigator Assessment
Of 5 RET TKI-naïve patients: 2 with confirmed PRs at 30 mg QD (DORs: 5.6 and 5.8+ months) Of 9 RET TKI-pretreated patients: 2 have stable disease with tumor reductions of -27% and -17% Both patients remained on treatment awaiting next scan TPX-0046: Preliminary Efficacy by Investigator Assessment No
Slide 39: TPX-0131: A Next Generation ALK Inhibitor
TPX-0131: A Next Generation ALK Inhibitor
Slide 40: TPX-0131: Highly Potent, CNS Penetrant ALK Inhibitor
TPX-0131: Highly Potent, CNS Penetrant ALK Inhibitor Note: Data presented at 2021 AACR Conference. ¹ Shaw A et al., J Clin Oncol 37:1370-1379. TPX-0131 Differentiation Potently inhibit WT ALK, and multiple resistant mutations (solvent front, gatekeeper and compound) Solvent front mutation G1202R rep
Slide 41: Phase 1/2 FORGE-1 Study of TPX-0131 in ALK+ NSCLC
Phase 1/2 FORGE-1 Study of TPX-0131 in Patients with ALK+ NSCLC, Currently in Dose Finding Study Endpoints: Primary: Evaluate safety / tolerability and determine maximum tolerated dose (MTD) and / or recommended Phase 2 dose (RP2D) Secondary: Objective Response Rate (ORR) by RECIST 1.1 Phase 1 Dose
Slide 42: Discovery Programs
3 Turning Point —=* Therapeutics Discovery Programs
Slide 43: Discovery Program Focused on Dysregulated GTPase Signaling
PAK1/4 KRAS G12D Key downstream effectors RAF-MEK-ERK Established oncogenic driver Multi-tumor opportunity in subsets of pancreatic cancer, colorectal cancer and NSCLC Discovery Program Focused on Dysregulated GTPase Signaling, Which Plays a Central Role in Cancer Promotion and Progression Note: Fig
Slide 44: Financial Highlights
@ Turning Point Therapeutics Financial Highlights
Slide 45: Financial Highlights
Financial Highlights As of June 30, 2021 NASDAQ TPTX Cash, Cash Equivalents, and Marketable Securities $1.1B Basic Shares Outstanding 49.4M Fully Diluted Shares Outstanding 55.2M
Slide 46: Next-Generation Precision Oncology Medicines Company Overview
October 2021 Next-Generation Precision Oncology Medicines Company Overview
Turning Point Therapeutics — Investor Presentation (October 2021) on 6ix